Institution
Sorbonne
Education•
About: Sorbonne is a based out in . It is known for research contribution in the topics: Population & Medicine. The organization has 4393 authors who have published 4374 publications receiving 78507 citations.
Topics: Population, Medicine, Computer science, Environmental science, Geology
Papers published on a yearly basis
Papers
More filters
••
Oxford Health NHS Foundation Trust1, University of Oxford2, Kyoto University3, University of Bern4, Sorbonne5, Paris Descartes University6, Cochrane Collaboration7, Warneford Hospital8, Technische Universität München9, Radboud University Nijmegen Medical Centre10, Oregon Health & Science University11, University of Bristol12, Stanford University13
TL;DR: This work aimed to update and expand previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder, and found that all antidepressants were more effective than placebo.
1,697 citations
••
TL;DR: Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance.
Abstract: Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide. To monitor the spread of artemisinin resistance, a molecular marker is urgently needed. Here, using whole-genome sequencing of an artemisinin-resistant parasite line from Africa and clinical parasite isolates from Cambodia, we associate mutations in the PF3D7_1343700 kelch propeller domain ('K13-propeller') with artemisinin resistance in vitro and in vivo. Mutant K13-propeller alleles cluster in Cambodian provinces where resistance is prevalent, and the increasing frequency of a dominant mutant K13-propeller allele correlates with the recent spread of resistance in western Cambodia. Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance. K13-propeller polymorphism constitutes a useful molecular marker for large-scale surveillance efforts to contain artemisinin resistance in the Greater Mekong Subregion and prevent its global spread.
1,639 citations
••
Leiden University Medical Center1, Ruhr University Bochum2, Ghent University Hospital3, Universidade Nova de Lisboa4, University of Zurich5, Paris Descartes University6, Sorbonne7, Semmelweis University8, VU University Medical Center9, University of Toronto10, University College London11, University of Leeds12, Erciyes University13, University of Lisbon14, University of Texas at Austin15, Ghent University16, Charité17, University of São Paulo18
TL;DR: The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA and three overarching principles and 13 recommendations deal with surgery and spinal fractures.
Abstract: To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.
1,147 citations
Authors
Showing all 4596 results
Name | H-index | Papers | Citations |
---|---|---|---|
Maxime Dougados | 134 | 1054 | 69979 |
Jean Piaget | 111 | 418 | 91230 |
Elie Azoulay | 111 | 716 | 43093 |
Olivier Hermine | 111 | 1026 | 43779 |
Serge Hercberg | 106 | 942 | 56791 |
Laurent Abel | 105 | 473 | 37932 |
Jean-Claude Baron | 105 | 522 | 36770 |
Capucine Picard | 103 | 414 | 35779 |
M. Barsuglia | 102 | 444 | 71205 |
Philippe Ravaud | 101 | 618 | 41409 |
Pierre Amarenco | 97 | 415 | 35259 |
Archana Singh-Manoux | 97 | 435 | 28730 |
E. Chassande-Mottin | 97 | 389 | 67213 |
Pilar Galan | 97 | 628 | 46782 |
Pierre Laurent-Puig | 96 | 530 | 47757 |